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Abstract: Sphingosine 1-phosphate (S1P), derived from membrane sphingolipids, is a pleiotropic
bioactive lipid mediator capable of evoking complex immune phenomena. Studies have highlighted
its importance regarding intracellular signaling cascades as well as membrane-bound S1P receptor
(S1PR) engagement in various clinical conditions. In neurological disorders, the S1P–S1PR axis is
acknowledged in neurodegenerative, neuroinflammatory, and cerebrovascular disorders. Modulators
of S1P signaling have enabled an immense insight into fundamental pathological pathways,
which were pivotal in identifying and improving the treatment of human diseases. However,
its intricate molecular signaling pathways initiated upon receptor ligation are still poorly elucidated.
In this review, the authors highlight the current evidence for S1P signaling in neurodegenerative
and neuroinflammatory disorders as well as stroke and present an array of drugs targeting the S1P
signaling pathway, which are being tested in clinical trials. Further insights on how the S1P–S1PR axis
orchestrates disease initiation, progression, and recovery may hold a remarkable potential regarding
therapeutic options in these neurological disorders.
Keywords: sphingosine 1-phoshate; sphingosine 1-phosphate receptor; S1P1–5; sphingosine
1-phosphate metabolism; sphingosine 1-phosphate antagonistst/inhibitors; sphingosine 1-phosphate
signaling; stroke; multiple sclerosis; neurodegeneration; fingolimod
1. Introduction—S1P Metabolism and Signaling
Three decades ago, sphingosine 1-phosphate (S1P) was identified as an intracellular signaling
agent in relation to calcium release from intracellular stores and metabolic adaptations [1]. The balance
between sphingosine and S1P, both metabolites of its precursor ceramide, and their subsequent
activation of effector kinases were shown to matter in imposing regulatory effects in the determination
of whether a cell is destined for cell death or proliferation [2]. The sphingolipid metabolism is almost
as complex as its protean intricacies to signaling pathways.
1.1. De Novo Sphingolipid Synthesis and Signaling at the Endoplasmic Reticulum
De novo sphingolipid biosynthesis is initiated in the smooth endoplasmic reticulum (sER) (Figure 1).
Here, the α-aminocarbonic acid serine and the lipid palmitoyl-CoA (PalCoA) are enzymatically
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processed by the key enzyme serine palmitoyltransferase (SPT)—which is negatively regulated
by ORM1-like protein 3 (ORMDL3) [3]—to 3-ketosphinganine [4–6]. Subsequent conversion of
3-ketosphinganine to S1P is promoted by enzymatic reactions including a reduction to sphinganine,
a synthase reaction to dihydroceramide, and a desaturase reaction to ceramide followed by deacylation
by ceramidase (CDase) and a phosphorylation by sphingosine kinase (SphK), which exists in two
isoforms (SphK1 and SphK2) [6–8]. In general, the formation of the ceramide and the sphingoid
bases represents the backbone of the sphingolipid metabolic pathway, as they can be utilized for
the synthesis of complex glycosphingolipids. Glycosphingolipids are crucial components of cellular
membranes [4,9], such as glucosylceramide or sphingomyelin manufactured by glucosylceramide
synthase (GCS) or sphingomyelin synthase (SMS), respectively [10,11]. These various enzymatic
reactions are not irreversible per se, since ceramide can be generated by sphingomyelin hydrolysis
and/or recycling of complex sphingolipids [10,12,13]. Ultimately, S1P can irreversibly be degraded
by S1P lyase into phosphoethanolamine (PE) and hexadecenal, both of which are being further
processed [14,15]; PE is used for the synthesis of phosphatidylethanolamine and hexadecenal is used
to replenish the PalCoA pool [15–18]. This cycle of de novo sphingolipid synthesis is tightly controlled
by NOGO-B, a protein located within the membrane of the endoplasmic reticulum, which inhibits
SPT [19,20]. Alternatively, S1P can be converted back to ceramides by dephosphorylation through
sphingosine 1-phosphate phosphatase (SGPP) 1 or SGPP2 [21,22], both of which are members of the
lipid phosphate phosphohydrolase (LPP) family [23]. This pathway can substantially contribute to the
synthesis of complex sphingolipids within a cell subject to cell type and metabolic demand [24,25].
Figure 1. Sphingolipid biosynthesis, sphingosine 1-phosphate (S1P) release, and signaling. S1P is
generated in different compartments within a cell. Nuclear S1P influences the balance between
chromosome density by histones and telomere length impacting on metabolic adaptations and cell
proliferation. De novo S1P synthesized at the smooth endoplasmic reticulum may be utilized for complex
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sphingolipid synthesis, crucial components of cellular membranes. Mitochondrial S1P influences
mitochondrial respiration by activating complex IV. S1P generated at the intracellular leaflet of
the plasma membrane (PM) is either used for intracellular signaling converging on the TNFα or
the PPARγ pathways or is exported to induce autocrine or paracrine stimulation transported by
apolipoprotein (ApoM)-containing high-density lipoprotein (HDL) or albumin and signaling via
membrane-bound S1P receptor (S1PR). Intracellularly, S1PR recruit different heterotrimeric G proteins
to initiate different signaling pathways, which results in the down-regulation of S1PR via β-arrestin
dependent recruitment of G protein receptor β-arrestin-regulated kinase 2 (GRK2), allowing dynamin
and moesin-dependent endosome recruitment. Endosomal S1PR are either recruited to the PM or
polyubiquitinylated by NEDD4-like E3 ubiquitin ligase WWP2 (WWP2) targeting S1PR for proteasomal
degradation. Endosomal remnants are fused with the lysosome (the place where complex sphingolipids
are degraded) to fully degrade proteinaceous or lipid cargo, ultimately replenishing the S1P pool.
The figure is a modified version of Cartier and Hla [26] and Kunkel et al. [23].
1.2. Synthesis and Signaling of Sphingosine 1-Phosphate in Mitochondria and at the Plasma Membrane
Mitochondrial S1P (Figure 1), produced by SphK2, facilitates oxidative phosphorylation (OXPHOS).
This effect was shown to be mediated by stabilizing the scaffolding protein prohibitin-2 (PHB2), which,
in turn, eases the recruitment of cytochrome c oxidase (CCO) and thus the assembly of complex IV of
the respiratory chain [23,27]. The most important site of S1P production is the plasma membrane (PM)
itself (Figure 1), which is composed of a lipid bilayer, predominantly consisting of an extracellular
(EC) and an intracellular (IC) phospholipid leaflet. Here, S1P is derived from sphingomyelin,
an integral component of cellular membranes [4]. Sphingomyelin is metabolized to S1P via the
enzymes sphingomyelinase (SMase), CDase, and sphingosine kinase 1 (SphK1) [28,29]. At this point,
S1P can either be exported using the multi-pass membrane proteins spinster homolog 2 (SPNS2) [30–33]
or major facilitator superfamily domain-containing protein 2B (MFSD2B) [30–32], respectively, or
employed for further immediate intracellular signaling cascades. In terms of intracellular signaling,
S1P can engage in tumor necrosis factor-α (TNF-α) receptor-associated factor 2 (TRAF2) [34] and
TRAF6-dependent TNF-α signaling [35]. S1P can either recruit the atypical protein kinase C (PKC)
subtypes ζ (PKCζ) or ι (PKCι) to sites of distinct membrane microdomains using receptor for activated
C kinase (RACK) proteins [36–38] or associate with the TRAF2 complex [34]. This, in turn, allows
the activation of the interleukin-1 (IL-1) pathway via TRAF6, cell survival, and convergence on the
TNF-α pathway downstream of TRAF2 [28,34,39–41]. The association with the TRAF2 complex is
said to occur by engaging with the N-terminal adjacent really interesting new group (RING) domain,
which allows activation of the intramolecular E3 ligase domain of TRAF2 [28,34,41]. The activation
of TRAF2′s E3 ligase lures receptor-interacting serine/threonine-protein kinase 1 (RIP1) in close
proximity, allowing polyubiquitination of its Lys63 residue. Polyubiquitination of Lys63 stimulates
RIP1′s kinase activity, which results in the phosphorylation of the inhibitor of nuclear factor κ-B
kinase (IκB-k). As a consequence, the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB)
signaling pathway is engaged, since IκB-k is now able to facilitate the down-regulation of the NF-κB
inhibitor α (IκBα). This culminates in the uncoupling of IκBα from NF-κB revoking its inhibitory effect
and allowing NF-κB’s nuclear translocation [28,34,35]. Crosstalk between TRAF2 and TRAF6 was
previously reported, as both can engage with atypical PKCs via protein p62 [39], are able to recruit
TGF-β-activated kinase 1 and MAP3K7-binding protein 3 (TAB3) [40,42], or can be polyubiquitinylated
given the presence of a RING domain in TRAF6 [43]. Moreover, a disruption of TRAF6 binding sites,
for example, only mildly impacts NF-κB signaling in the presence of TRAF2 and TRAF3 [44]. Beyond
the TNF-α signaling pathway, S1P signaling can vitalize adipogenesis, glucose (Glc) metabolism,
and β-oxidation via peroxisome proliferator activated receptor γ (PPARγ) [15,45,46]. By binding to
its His323 residue, S1P activates PPARγ, increasing the likelihood of an association with the PPARγ
co-activator 1β (PGC1β), a necessary co-transcription factor for nuclear translocation [46,47].
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1.3. Sphingosine 1-Phosphate Signaling in the Nucleus
SphK2, the predominant isoform in the sER and mitochondria [27,48], is also predominant in the
nucleus (Figure 1) [49–53]. Nuclear S1P was shown to be critically involved in influencing the balance
between cellular quiescence and proliferation. Hait et al., showed that S1P produced in the nucleus
binds to the class I histone deacetylases (HDAC) 1 and 2, which results in their inhibition [53]. In general,
HDAC1 and HDAC2′s function lies in removing acetyl residues coupled to the α-aminocarbonic
acid lysine close to the amino-terminal end of the histone protein H3 [54–56]. Therefore, the removal
of these negatively charged residues culminates in a net positive charge of H3, increasing its tight
association with the negatively charged deoxyribonucleic acid (DNA). Ultimately, the inhibition of
HDAC1/2 enhances transcription of cyclin-dependent kinase inhibitor 1 (p21) and the proto-oncogene
c-Fos (c-fos) [53]. Conversely, S1P may bind to human telomerase reverse transcriptase (hTERT) [57],
which may allow makorin ring finger protein 1 (MKRN1) to dissociate due to competitive binding
sites [57,58]. This signaling cascade results in telomere maintenance, cell proliferation, and tumor
growth [57].
1.4. Sphingosine 1-Phosphate in Autocrine and Paracrine Signaling
Detailed experimental evidence is available for the mechanisms of “inside-out” autocrine and
paracrine S1P signaling. After release into the extracellular compartment via SPNS2 [30–33] or
MFSD2B [30–32], S1P is swiftly bound by its chaperones due to its hydrophobic character. These
chaperones are apolipoprotein M (ApoM)-containing high-density lipoprotein (HDL)—to some extent
also to very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) [59,60]—or albumin,
respectively [61–63]. Subsequently, upon release and chaperoning by HDL or albumin, ligation of
the five known heptameric G protein-coupled S1P receptors (S1PR) 1–5 (S1P1–5) (Figure 1) [64–69]
can result both in autocrine and paracrine signaling [70–72]. Signaling via S1PR is tightly regulated.
Fine tuning of S1P-S1PR signaling may occur via post-translational modifications, e.g., through
palmitoylation by the palmitoyltransferase DHHC5 (DHHC5) [73] and, at some point, termination
of the signaling cascade may be achieved by β-arrestin-dependent recruitment of G protein-coupled
receptor kinase 2 (GRK2), which phosphorylates S1PR, resulting in dynamin and moesin dependent
establishment of the endosome [74–79]. At this point, re-routing, i.e., recycling of the receptor to the
PM [80], polyubiquitination by the NEDD4-like E3 ubiquitin protein ligase WWP2 (WWP2) resulting
in proteasomal degradation [81], or fusion with the lysosome in order for complete proteinaceous and
lipid residue degradation can occur (Figure 1) [82–84]. The latter endolysosomal salvage pathway
is of particular importance for cellular homeostasis and disassembly of complex sphingolipids to
ceramides or allowing endolysosomal SphK1 to produce S1P, respectively [85–87]. The herein discussed
mechanisms are briefly summarized in Figure 1.
1.5. External Action of Sphingosine 1-Phosphate through S1PR
With respect to S1PR ligation, the de facto signal triggered is dependent upon the S1PR subtype,
the presence of co-regulatory agents, and the heterotrimeric G protein recruited. To date, five bona
fide cognate receptors for S1P are known, namely S1P1–5 (Figure 2) [88]. S1P1, the most commonly
expressed S1P receptor in the brain [89], appears to be most selective as it binds only to Gαi/0 [66,90].
S1P2, also binding to Gαi/0, is capable of associating with Gαq, G12/13, and Gαs [66,88,90], however, it
couples most efficiently with G12/13, subsequently activating the small GTPase Rho [91–93]. S1P3 is said
to couple with Gαi/0, Gαq, and G12/13, although a higher affinity/likelihood for association with Gαq was
observed, ultimately resulting in intracellular Ca2+ enrichment and activation of PKC [92,94]. S1P4 and
S1P5 can couple to Gαs, Gαq, and G12/13 [88,95]. Regarding the intracellular signaling pathways
triggered, the interested reader is referred to reviews entirely dedicated to detailing molecular signaling
and transcriptional cascades triggered in appreciation of the heterotrimeric G protein recruited [96–99].
Regarding receptor activation or inhibition due to the presence of co-regulatory agents, S1P1 can be
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activated by cluster of differentiation molecule (CD) 44 (CD44) (hyaluronic acid receptor) or activated
Protein C (aPC) [100,101], whilst inhibition by CD69, S1P2 (in dermal γδ T cells), or LPA1 was reported
previously [102–104]. Unlike NOGO-B, NOGO-A, a multi-pass PM and ER protein whose expression
is confined to the central nervous system (CNS), was shown to activate the S1P binding domain ∆20 of
S1P2, thereby restricting neurite outgrowth via engagement with the G13-RhoA signaling pathway [105].
Moreover, conjugated bile acids (CBAs) and FAM19A5 were other activators of S1P2 [106,107]. Figure 2
gives a synopsis signaling cascades upon S1P1–5 ligation.
Figure 2. Sphingosine 1-phosphate receptors, canonical pathways, and functions triggered.
The currently discovered S1P receptors 1–5 (S1P1–5) are displayed. S1PR are naturally activated by S1P
and to some extent by dihydro-S1P (sphinganine 1-phosphate) and phyto-S1P (4-hydroxysphinganine
1-phosphate), but also competitive/allosteric activation and inhibition by other molecules are described.
Upon activation, S1PR can recruit various heterotrimeric G proteins, which, in turn, allow a finely tuned
intracellular signaling cascade to be evoked by means of both Gα and Gβγ. Thus, differential S1PR
expression in response to varying environmental lipid contexts, i.e., S1P, dihydro-S1P, and phyto-S1P,
respectively, may result in a context- and cell type-dependent function triggered.
2. Implications of Sphingolipids in Neurological Disorders
2.1. The Sphingolipid Metabolism in Neurodegenerative Disorders
Neurodegenerative diseases are commonly characterized by intracellular or extracellular
aggregation of misfolded proteins. These diseases most commonly comprise Alzheimer’s disease
(AD), characterized by the proteins amyloid-β and tau, Parkinson’s disease (PD; α-synuclein),
and amyotrophic lateral sclerosis (ALS), in which TAR DNA-binding protein 43 deposition is
observed [108]. With respect to the accumulation of the ontogeny of the protein misfolded, different
classifications of neurodegenerative conditions were established, denoted as tauopathies [109],
synucleinopathies [110], or prion diseases [111] (Figure 3).
Regarding AD, increasing evidence supports the crosstalk between sphingolipids and aberrant
protein aggregation [112,113]. Amyloid-β-peptide (Aβ) is cleaved from amyloid precursor protein
(APP) by the β- and the γ-secretase enzymes, while α-secretase acts within the Aβ sequence [114].
APP cleavage and the release of Aβ from the PM subsequent to its production in lipid rafts are
influenced by lipid composition [115,116]. Alterations in membrane lipid composition have a key role
in the subsequent subcellular transport and trafficking of these proteins [114,116,117].
Perturbations in the neurovascular unit (NVU) result in a compromised barrier function and
dysregulation and reduction in cerebral blood flow (CBF), which is implied to be involved in the
pathogenesis of AD [118–127]. Vascular tightness via tight junctions is influenced by the sphingolipid
metabolism. In that regard, acid SMase activity and ceramide production in endothelial cells were
linked to vascular permeability [128]. Conversely, the acid SMase inhibition maintained enhanced tight
junction regulation [128]. Similar mechanisms were observed to happen in astrocytes [129]. In brain
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tissue of AD patients’, studies showed increased ceramide levels and decreased sphingomyelin and
S1P levels [130–134]. A study on AD by Katsel et al., found a significant up-regulation of messenger
ribonucleic acid (mRNA) of phospholipid phosphatase 3 (PLPP3) and S1P lyase 1 (SGPL1) at early
stages after diagnosis, suggesting a lack of S1P as a spatiotemporal function may contribute to the
degeneration of neurons [135]. Besides, Ceccom et al., reported in an immunohistochemical study of
AD a reduction of SphK1 accompanied by enhanced S1P lyase expression in frontal and entorhinal
human cortices to be accountable for the perturbed S1P metabolism observed, contributing to the
deposition of amyloid and ultimately to neuronal damage [136]. More recently, Dominguez et al.,
described that the subcellular localization of S1P’s production, e.g., by a disrupted equilibrium between
cytosolic and nuclear SphK2, conferred pathogenic effects of S1P in AD [137].
Figure 3. Clinical significance of distorted sphingosine 1-phosphate signaling in neurological
disorders. Perturbed S1P signaling has been reported in various clinical conditions ranging from
autoimmunity, infection, and cancer. S1P signaling was also shown to play a detrimental role in several
neurological diseases, including neurodegenerative and neuroinflammatory conditions, but equally in
cerebrovascular insults resulting in stroke or subarachnoid hemorrhage. The yellow patches refer to
demyelinated/inflamed areas in the white matter. The area of the grey matter (grey) highlighted in blue
denotes the infarcted region. This region is perfused by the middle cerebral artery (here blocked by an
embolus), a branch of the cerebral vessel system (red).
With respect to PD, a chronic progressive disorder characterized by the degeneration of
dopaminergic neurons in the pars compacta of the substantia nigra, emerging evidence has elucidated
the role of mitochondrial and endolysosomal pathways and their interplay with ceramides in its
pathogenesis. Xilouri et al., focused on α-synuclein degradation and suggested, in 2008, an impairment
of neural autophagy-lysosomal pathways to be responsible for α-synuclein accumulation, unraveling a
causal link between the pathogenic event and the initiation as well as the progression of the disease [138].
Later, further studies confirmed this hypothesis [139,140].
Glucocerebrosidase (GBA) mutations were found in subjects with parkinsonism [141,142],
which were previously reported to predispose to the development of Lewy body disorders (LBD) [143].
Concerning LBD, Bras et al., investigated the neuronal ceramide metabolism and reported that several
genes known to confer the risk of LBD development converge on the ceramide metabolism, although
this remains to be confirmed neurohistologically [144]. In addition, implications in the pathogenesis of
synucleinopathies were supported by descriptions of mutations in the GCase gene (GBA1) and altered
sphingolipid pathways [145,146].
Mazzulli et al., could delineate that glucosylceramidase (GlcCer), the GCase substrates, enhanced
the rate of α-synuclein oligomerization [147]. Recently, it was shown that the actual sphingolipid
subspecies carry various potentials to cause formation of oligomeric α-synuclein, particularly in
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reflection of comparing in vitro with in vivo data [148]. Here, glucosylceramide, glucosylsphingosine,
sphingosine, and S1P were shown to promote β-sheeted (oligomerized) structures of α-synuclein [148].
Somewhat aside of the molecular establishment of the aforementioned classifications,
neurodegeneration is associated with the accumulation of most commonly CAG trinucleotide repeats,
which encode for multiple glutamine residues to be translated, inevitably causing a toxic gain of
function of the mutant protein [149]. The best-known condition for trinucleotide repeat disorders is
Huntington’s disease (HD) [150]. In HD, Di Pardo et al., showed an increase in SGPL1 in the striatum
and the cortex and a decrease of SphK1 in the striatum of human post-mortem tissues, which were
reflected by similar changes in mouse models of HD [151]. Moreover, the R6/2 mouse model revealed
reduced levels of S1P [151,152] despite an up-regulation of SphK2. In contrast, no change was seen in
either SphK2 in the YAC128 model or in humans [151]. Unfortunately, no data are currently available
regarding S1P levels in YAC128 mice nor in human post-mortem tissues [153]. These findings warrant
further investigations into the usability of druggable targets within the sphingolipid metabolism in HD.
Regarding ALS, a study by Henriquez et al., demonstrated a link between ALS severity and
gene expressions or metabolite levels for sphingosine, ceramide (d18:1/26:0), SGPP2, SphK1, and UDP
galactosyltransferase 8A (UGT8A) [154]. Shedding light on the therapeutic potential of the sphingolipid
metabolism in ALS, Potenza et al., reported an improved neurological phenotype and an extended
survival after fingolimod, a prodrug that becomes phosphorylated after application in vivo and acts as
a receptor agonist against almost unanimously all S1PR—except for S1P2 [155,156], administration in
mSOD1G93A mice [157].
2.2. The Sphingolipid Metabolism in Neuroinflammatory Disorders
Multiple sclerosis (MS) represents an inflammatory disorder of the brain and the spinal cord
featuring inflammation, demyelination, and neurodegeneration [158] (Figure 3). Over the last decades,
murine experimental autoimmune encephalomyelitis (EAE) models have been used to decipher the
mechanisms responsible for disease pathogenesis and progression and to identify druggable targets in
order to develop therapeutics for multiple sclerosis [159–161]. It has been known for some time that
the S1P metabolism can be exploited to slow disease progression in MS, e.g., by fingolimod, causing
lymphocyte sequestration and ultimately preventing auto-reactive immune cell infiltration into the
CNS [162]. The potency of exploiting the S1P–S1PR axis by fingolimod in EAE was first shown in rats
by Brinkmann et al. [155], implicating the feasibility to exploit S1PRs to influence lymphocyte egress.
Subsequently, other studies have added to this observation [163–165]. Another report unveiled that
prophylactic and therapeutic treatment with fingolimod resulted in suppression of EAE [166]. Choi et
al., reported, in 2011, that a decline in disease severity of EAE by fingolimod involved astrocytic S1P1
modulation as well, thus a loss of S1P1 in astrocytes reduced disease severity, demyelination, axonal
loss, and astrogliosis [167], arguing for additional CNS-specific effects of fingolimod in addition to
lymphocyte redistribution. A recent study identified potential long-term effects caused by S1PR ligation.
These long-term effects, according to Eken et al., confer an impact not only on lymphoid sequestration
but similarly on non-lymphoid tissue regulatory T cell (TREG) distribution, and, more importantly,
on reducing the memory TREG pool in favor of effector TREG [168]. This could have implications
for appropriate T cell zone access in lymph nodes via C-C chemokine receptor type 7 (CCR7) and
subsequently their ability to control auto-reactive T cells in vivo [168,169]. These findings warrant
further investigation into the precise mechanisms by which enzymes and lipids involved in the
generation of S1P and their effects were linked to disease progression and treatment.
Cruz-Orengo et al., identified S1P2 in the inbred SJL mouse strain as a sex- and strain-specific,
disease-modifying molecule promoting the breakdown of adherens junctions, thus leading to
blood-brain barrier (BBB) leakage, while antagonism of S1P2 signaling led to an amelioration of
disease severity in female mice [170]. BBB disruption could also be induced by ceramides, resulting
in an increased migration of monocytes [129]. Moreover, Lopes et al., demonstrated that acid
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SMase-derived ceramide regulates intracellular adhesion molecule 1 (ICAM-1) function during T cell
transmigration across brain endothelial cells [171].
Concerning S1P receptor expression profiles in the disease model of EAE, mRNA for S1P1 and
S1P5 in the spinal cord was down-regulated, and an up-regulation of S1P3 and S1P4 mRNAs occurred
in the EAE model, which was reversable by fingolimod in accordance with structural restoration of the
CNS parenchyma given a restriction to autoimmune T cell infiltration [166]. S1P3 was shown to be
involved in promoting systemic inflammation via activation of dendritic cells [172]. Concerning S1P3
signaling in MS, Fischer et al., suggested that an increased expression of S1P3 in EAE was likely due to
astrocyte activation; however, its actual sequelae regarding detrimental effects (e.g., astrogliosis) and
beneficial effects (e.g., remyelination) could not be established [173]. Apart from astrocytes, the same
group reported enhanced SphK1 expression in macrophages of MS lesions [173]. A more definitive
proof of S1P3‘s importance regarding an inflammatory cascade triggered in astrocytes was reported
by Dusaban et al. [174]. The authors demonstrated S1P3 to be up-regulated in astrocytes and to be
able to engage with transforming protein RhoA (RhoA), and S1P3 ligation was shown to promote IL-6,
vascular endothelial growth factor A (VEGFa), and cyclooxygenase-2 (COX-2), which was accompanied
by an increase of SphK1 and S1P3 in vitro [174].
Neuromyelitis optica (NMO) spectrum disorders can also be classified as pertaining to the
group of inflammatory brain disorders. Their hallmark feature was initially introduced by Devic
and Gault [175,176] and characteristically consisted of a severe complement-mediated damage to
the optic nerves and the spinal cord [177]. The discovery of highly specific serum autoantibody
marker (NMO-IgG) eventually helped to differentiate this spectrum of disorders from MS and the prior
interpretation as one entity [178,179]. Several reports have suggested that treatment with fingolimod
in NMO may be contraindicated due to adverse events and worsening of disease severity [180–183].
However, exploitation of the sphingolipid metabolism to treat patients with NMO should not be
excluded prematurely. Matsushita et al., demonstrated significantly higher levels of TH1-related,
i.e., C-C motif chemokine 4-like (CCL4) and C-X-C motif chemokine (CXC) 10 (CXCL10), and the
TH-17-related (and neutrophil-related) chemokine CXCL8 (IL-8) in NMO patients [184]. STAT3,
which was recently shown to be linked to S1P signaling [185–187], is known to control the expression
of chemokines and chemokine receptors in the recruitment of neutrophils [188] and T cells [189].
With respect to the mechanisms by which S1P signaling is tied to chemokine production and immune
cell migration, studies revealed an interplay between S1PR and chemokine-driven migration of
non-activated and naïve T cells [190]. In addition, binding of S1P produced by SphK1 to TRAF2 and
cellular inhibitor of apoptosis 2 (cIAP2) in response to IL-1 signaling results in NF-κB activation [34].
This represents a relevant step in the recruitment of mononuclear cells to sites of sterile inflammation
by means of interferon regulatory factor 1 (IRF1) expression and the resultant availability of the
chemokines CXCL10 and CCL5 [191]. Therefore, mediation of the complex pathways of immune cell
recruitment/trafficking, potentially resulting in favorable TREG recruitment without disrupting TH-17 or
follicular T-helper cell (TFH) sequestration, may hold the potential for future S1P metabolism-associated
therapeutic perspectives in NMO [192].
Autoimmune conditions, such as systemic lupus erythematosus (SLE) or Hashimoto’s disease,
may present themselves with neurological pathology [193–195]. Therefore, due to their clinical
heterogeneity, affecting potentially any organ of the body such as renal involvement may advise future
neurological therapeutic perspectives. In that regard, studies have shown elevated S1P serum levels
in patients with juvenile onset SLE [196] as well as in MRL-lpr/lpr mice [197]. In light of therapeutic
targets for SLE, previous studies have concentrated on lupus nephritis. Here, fingolimod showed
positive effects on survival, suppressing the continuation of autoimmunity [197]. In the context of
murine lupus nephritis, in the NZB/W mouse model as well as in BXSB mice, fingolimod also proved
to be beneficial [198–200]. However, inhibition of SphK2 in the MRL-lpr/lpr model could not convey
protection from SLE [196]. These promising results prompted testing of cenerimod, a selective S1P1
modulator (NCT02472795).
Cells 2020, 9, 1515 9 of 37
Other conditions denoted by aberrant inflammatory immune cell activation with a potential to
cause immune encephalitis have been reported recently. For example, in autoimmune thyroiditis
an enhanced expression of SphK1, S1P, and S1P1 converging on STAT3 activation in CD4+ T cells
was demonstrated in mice by Han et al. [201]. Conversely, administration of fingolimod to these
NOD.H-2h4 mice conferred the potential to reduce disease severity accompanied by a reduction of
STAT3-related cell types, i.e., TH1, TH17, and TFH cells [201].
2.3. The Sphingolipid Metabolism in Cerebrovascular Diseases
Lipid signaling plays pleiotropic roles in cerebral ischemia. In recent years, mounting evidence
has emerged depicting the relationship between the sphingolipid metabolism and stroke (Figure 3).
Studies have demonstrated that the driving force of neuroinflammation following cerebral ischemia are
T cells. They migrate into the brain and amplify the initial detrimental damage [202–205]. Conversely,
lymphocyte-deficient mice were shown to be protected from ischemic damage [206,207].
The S1P analogue and the S1P1 functional antagonist fingolimod, originally derived from the
fungal natural product ISP-1, was first synthesized in 1992 [208]. It impairs the egress of lymphocytes
from primary and secondary lymphoid organs [155] and exerts immunomodulatory effects and
non-immunological mechanisms [65,167,209–211]. Fingolimod was shown to provide protection from
ischemic stroke and intracerebral hemorrhage [89,204,211–217], leading to the initiation of clinical
studies demonstrating the efficacy of fingolimod for patients with acute ischemic stroke and improving
clinical outcomes in patients with intracerebral hemorrhage [218]. In addition to reduced infarct
volumes and improved neurological scores at 24 and 72 h after middle cerebral artery occlusion (MCAO;
a commonly used animal model for ischemic stroke), fingolimod showed a deactivation of caspase-3,
a reduction of terminal deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick
end-labeling (TUNEL-) positive neurons, an activation of RAC-alpha serine/threonine-protein kinase
(Akt) and extracellular-regulated kinase (ERK), and a Bcl-2 up-regulation, delineating an anti-apoptotic
effect in neurons [211].
Moreover, studies have reported a role of S1PR in the preservation of endothelial barrier
integrity [64,219], and phosphorylated fingolimod promotes the establishment of adherens junction in
endothelial cells, i.e., an enhanced endothelial barrier function [65,209].
In contrast, Liesz et al., investigated the effect of fingolimod in permanent murine cerebral
ischemia without achieving a significant reduction of infarct volumes and behavioral dysfunction
despite effective lymphopenia [220]. In addition, Cai et al., unveiled no improvement in functional
outcome and BBB integrity in large hemispheric infarctions and administration of fingolimod, either
alone or in conjunction with recombinant-tissue plasminogen activator (rt-PA) [221]. Sanchez suggested
that S1P1 desensitization and/or degradation would potentially evoke detrimental effects on neurons
and/or endothelial cells in the context of stroke. Therefore, the dosing and the timing of fingolimod
administration seemed to be pivotal for its protective effects [222]. This is in accordance with a previous
study by Brait et al., who showed that S1P1 fosters protective effects regarding infarct volume after
MCAO, however, only if the associated lymphopenia persists for at least 24 h [223].
SphK2 appears to wield an ambiguous nature in various disorders. SphK2 is the predominant
S1P-synthesizing isoform in normal brain parenchyma [224] and particularly in cerebral microvascular
endothelial cells [225]. SphK2 was recently shown to induce ischemic tolerance to stroke in C57BL/6
mice [226]. SphK2 is preferentially utilized to confer the neuroprotective effects of fingolimod, as it has
a 30-fold higher affinity to the prodrug compared to SphK1 [225]. Mice lacking the SphK2 show larger
ischemic lesions 24 h after 2 h of MCAO in comparison with wild-type animals [216], thus reinforcing
the importance of extracellular signaling of S1PR. Moreover, studies have demonstrated that SphK2
predominates SphK1 in the phosphorylation of fingolimod in vitro [225] and in vivo [227]. In addition,
hypoxia increases the expression and the activity levels of the SphK2 isoform in brain microvasculature,
subsequently promoting ischemic tolerance [228]. In contrast to SphK2, S1P2 is characterized as a key
regulator of the pro-inflammatory phenotype of the endothelium [229] and promotes ischemia-induced
Cells 2020, 9, 1515 10 of 37
vascular dysfunction [230]. Conversely, S1P generated by SphK1 potently facilitates the expression
of IL-17A in activated microglia, thereby supporting neuronal apoptosis in cerebral ischemia [231].
This is in support of a study by Zheng et al., who found an enhanced expression of SphK1 in microglia
96 h after MCAO [232]. Subsequently, a cortical knockdown of SphK1 resulted in reduced infarct areas
and less severe neurological deficits were observed [232].
Studies have highlighted the critical role of S1P2 in ischemia-reperfusion injury, confirming that
genetic deletion or inhibition of S1P2 could block the development of hemorrhagic transformation
and cerebral edema by inhibiting the matrix metalloproteinase-9 (MMP-9) activation in endothelial
cells [230]. It was shown previously that the use of fingolimod conveyed a reduced risk of hemorrhagic
transformation after thromboembolic occlusion [233]. In regard to these findings, the benefit of
fingolimod in relation to hemorrhagic transformation was tested in randomized open-label multi-center
trials [234,235]. Wan et al., focused on microRNA-149-5p and demonstrated its regulatory function on
the permeability of the BBB after transient MCAO in rats by targeting S1P2 of pericytes [236]. In their
study, the expression of S1P2 in pericytes increased at an early stage during ischemia/reperfusion,
which was associated with an aggravation of BBB permeability in vivo and in vitro [236]. An engineered
S1P chaperone, ApoM-Fc, maintained sustained S1P-S1PR signaling, resulting in a promoted function
of the BBB after MCAO [237]. Another study puts emphasis on the importance of S1P in ameliorating
the effects of stroke, as they reported reduced S1P lyase activity and a preferential synthesis of S1P and
other sphingolipids in response to hypoxia [238].
In opposition to S1P2, pathogenic mechanisms of S1P1 and S1P3 in cerebral ischemia rely on
microglial activation [239,240]. Moreover, the same group elucidated the importance of S1P1-regulation
in promoting a pro-inflammatory M1 polarization of astrocytes, which was brought about by the
intracellular signal transducers ERK1/2, p38, and JNK MAPK favoring brain damage after cerebral
ischemia [241]. Furthermore, Zamanian et al., examined reactive astrogliosis in response to either MCAO
or LPS and showed Pentraxin-related protein PTX3 (PTX3), tumor necrosis factor receptor superfamily
member 12A (TNFRSF12A), and S1P3 to be markers of reactive astrocytes after MCAO [242]. Liddelow
et al., termed them “A1” and “A2” in analogy to the macrophage nomenclature [243]. Interestingly,
S1P3 was induced 46-fold after MCAO but only 6.4-fold by LPS. Under physiological circumstances,
astrocytes were reported to express mainly S1P1 and S1P3, contrasting with very low levels for S1P2
and S1P5 [244–246]. However, in a recent study by Karunakaran et al., the authors demonstrated
the importance of S1P2 in microglial activation conferring impaired autophagy and propagating the
inflammatory response in the BV2 microglial cell line [247]. Interestingly, similar effects were observed
by the group after exogenous S1P administration or genetic knock out of SGPL1 [247].
S1P signaling is also functionally linked to influencing the pathophysiology during subarachnoid
hemorrhage (SAH). In accordance with the detrimental effects caused by S1P2 ligation in
ischemia-reperfusion mentioned before, Yagi et al., demonstrated that S1P signaling increases vascular
tone in the context of SAH, thus worsening neurological scores [248]. By employing a selective
S1P2 antagonistic treatment systemically using JTE013, they were able to set bounds to the extent of
myogenic reactivity and to restore neurological scores to sham levels when administered instantly
after SAH induction [248].
The various conditions that perturbed S1P signaling has been linked with are summed up in
Figure 3.
3. Insights into Current and Future Therapeutic Perspectives
Almost a decade ago, the FDA approved the first drug aimed to interfere with the S1P-S1PR
signaling cascade, fingolimod, in 2010 [162]. Due to fingolimod’s preference for S1P1 and the strong
activation of this receptor subtype, S1P1 eventually becomes down-regulated, resulting in a long-lasting
functional antagonism that accounts for fingolimod-induced lymphocyte trapping in primary and
secondary lymphoid organs. Consequently, this lymphocyte sequestration prevents auto-reactive T
cells to migrate to the brain and therefore reduces the ferocious neurotoxic damage to myelin-associated
Cells 2020, 9, 1515 11 of 37
proteins in patients with multiple sclerosis [158,249]. Nevertheless, due to its lack of specificity, a range
of adverse effects (e.g., first-dose bradycardia [250], macular edema [251], elevated liver enzymes [252],
and lymphopenia warranting vigilance regarding occurrence of infections [253–255]) is inevitable [256].
The endeavor to circumvent these unwanted drug effects led to the development of more tailored
drugs aimed at selectively activating or inhibiting checkpoints within the sphingolipid metabolism
on demand. To date, there is a huge number of clinical trials either completed (C), terminated
(T), or momentarily being conducted in various clinical conditions examining the pharmacological
exploitability of drugs designed to beneficially influence targets within the sphingolipid metabolism.
A selection of these studies is presented below (Table 1). It is advisable to conceive that potentially all
molecules/agents addressed in Figures 1 and 2 may represent future therapeutic targets.
Safingol, which targets PKC and non-selectively sphingosine kinases (SphK) [257], was identified
in 1995 [258]. Safingol is now being tested in various cancer settings, since it is safe to co-administer with
cisplatin and exerts tumoricidal effects [259,260]. Similarly, another drug targets SphK. The compound
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridine-4-ylmethyl)amide (ABC294-640) selectively
inhibits SphK2. ABC294640 was identified in 2010 [261] and mechanistically competes with sphingosine
for binding sites at SphK2. This, in turn, allows sphingosine and ceramides levels to increase
(due to inability/slower rate of enzymatical conversion to S1P), facilitating apoptosis-inducing
pathways [2,6,262]—a mechanism that was recently studied in various cancer therapies [263–266].
In that regard, conceivably, the exploitation of PKC and SphK subtypes in neurological conditions
where their homeostasis of molecular activation, proliferation, and apoptosis is perturbed by crucially
diminishing the S1P level within a cell and its immediate effects via PKC appears intuitive. This remains
apprehensible, since S1P levels were previously shown to be enhanced to the disadvantage of its
pro-differentiative and pro-apoptotic precursor ceramide [267,268].
Previously, a S1P-directed therapeutic agent was introduced [269]. The S1P-specific monoclonal
antibody sonepcizumab (LT1009) is being tested in conditions where pathologies of the vasculature
system occur [270–272].
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Table 1. Trials of drugs interfering with the sphingosine 1-phosphate metabolism in clinical conditions. (C), completed; (T), terminated; (S), suspended (one study
currently on halt due to COVID-19-related recruitment stop); SPHK1/2, sphingosine kinase 1/2; PKC, protein kinase C; S1P, sphingosine 1-phosphate; S1Pn, S1P
receptor ‘n’.
Target Compounds (Mechanism of Action) Indications ClinicalTrials.gov Identifier Phase
SPHK1/2, PKC inhibitor Safingol
Solid tumor NCT01553071 I




Non-resectable, perihilar cholangiocarcinoma (extra- and intrahepatic)
NCT03377179 II
NCT03414489 n/a
Pancreatic cancer, adult solid tumor (unspec.) NCT01488513 I (C)
Multiple myeloma NCT02757326 I, II (T)
S1P
n/a
Bacterial pneumonia NCT04007328 II, III
Food Allergy, anaphylaxis NCT01776489 n/a
Asthma NCT04134351 n/a
Pneumonia, chronic obstructive pulmonary disease, asthma NCT03473119 n/a
Sonepcizumab [LT1009]
(S1P-specific mAb)
Solid tumors NCT00661414 I (C)
Neovascular age-related macular degeneration NCT00767949 I
Exudative age-related macular degeneration NCT01414153 II (C)
Pigment epithelial detachment NCT01334255 I (T)
Renal cell carcinoma NCT01762033 II (T)
S1P lyase LX3305
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Table 1. Cont.
Target Compounds (Mechanism of Action) Indications ClinicalTrials.gov Identifier Phase
S1P1
n/a




Atopic dermatitis ACTRN12617000763347 II
Rheumatoid arthritis ACTRN12617001223325 II
BMS-986104 Rheumatoid arthritis (healthy volunteers) NCT02211469 II (C)
Cenerimod [ACT-334441]
(S1P1 agonist)

















Subacute cutaneous lupus erythematosus NCT01294774 II (C)
Hematological malignancies NCT01830010 I (C)










Plaque psoriasis NCT00852670,NCT01208090 II (C)







Pharmacokinetics NCT02126956 I (C)
Safety and tolerability NCT02029482 I (C)
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Table 1. Cont.
Target Compounds (Mechanism of Action) Indications ClinicalTrials.gov Identifier Phase
S1P1, S1P3, S1P4, S1P5
Fingolimod [FTY720]
(S1PR modulator, S1P1 functional
antagonist)


































Multiple sclerosis (autonomic nervous system dysfunction) NCT02048072 IV (C)
Multiple sclerosis (fatigue) NCT01490840 IV (T)
Multiple sclerosis (cognitive deficits) NCT02141022 n/a
Primary progressive multiple sclerosis NCT00731692 III (T)
Cells 2020, 9, 1515 15 of 37
Table 1. Cont.
Target Compounds (Mechanism of Action) Indications ClinicalTrials.gov Identifier Phase






































Relapsing–remitting multiple sclerosis (cognition, brain volume loss) NCT02575365 IV (T)
Relapsing–remitting multiple sclerosis (depression) NCT01436643 IV (T)
Acute demyelinating optic neuritis NCT01757691 II (T)
Amyotrophic lateral sclerosis NCT01786174 II (C)
Intracerebral hemorrhage (hypertensive, intraparenchymal), cerebral edema NCT04088630 I
(Acute) stroke, (cerebro-) vascular accident, cerebral stroke NCT02002390 II (C)
Chemotherapy-induced peripheral neuropathy (numbness, pain, tingling) NCT03943498 I
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Table 1. Cont.
Target Compounds (Mechanism of Action) Indications ClinicalTrials.gov Identifier Phase
S1P1, S1P3, S1P4, S1P5
Fingolimod [FTY720]
(S1PR modulator, S1P1 functional
antagonist)
Chronic inflammatory demyelinating polyradiculoneuropathy NCT01625182 III (C)
Breast carcinoma NCT03941743 I
Glioblastoma, anaplastic astrocytoma NCT02490930 I (C)
Coronavirus disease (COVID-19) NCT04280588 II
Asthma NCT00785083 II (C)
Rett syndrome NCT02061137 II (C)
Schizophrenia NCT01779700 II (C)
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Table 1. Cont.






















Healthy volunteers NCT00422175 I (C)
Multiple sclerosis NCT03623243 III
Relapsing-remitting multiple sclerosis NCT01185821,NCT00879658 II (C)








Hepatic impairment NCT01565902 I (C)
Hemorrhagic stroke, intracerebral hemorrhage (ICH) NCT03338998 II (S)
Renal impairment NCT01904214 I (C)
Cells 2020, 9, 1515 18 of 37
Table 1. Cont.
















Systemic lupus erythematosus NCT02307643 I (C)
Plaque psoriasis NCT01987843 II (C)
Inflammatory bowel disease NCT01666327 I (C)
Etrasimod [APD334]
Primary biliary cholangitis NCT03155932 II (T)









Pyoderma gangrenosum NCT03072953 II (T)
Crohn’s disease NCT04173273 II
Atopic dermatitis NCT04162769 II
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Conversely to the aforementioned mechanisms inevitably reducing the amount of S1P available,
drugs either mimicking S1P effects at the receptor site or actually increasing S1P levels have been
designed. The S1P lyase inhibitor LX3305 is currently being investigated in rheumatoid arthritis
as an alternative to therapies with biologicals [273]. Conceptually, LX3305′s tentative application
in neurological conditions where S1P is reduced/disturbed appears undoubtedly apprehensible,
e.g., in neurodegenerative disorders such as Alzheimer’s disease [134], Parkinson’s disease [274],
Huntington’s disease [151,153], or amyotrophic lateral sclerosis [154]. Several diseases have been
implicated in aberrant S1PR-specific signaling pathways. In that regard, several drugs specifically
designed to interact with S1P1 are available to date. AKP11, for example, was compared against
fingolimod in a rodent model of multiple sclerosis and was associated with a higher degree of
endosomal receptor recycling upon withdrawal, lesser extent of proteasomal degradation, and milder
and more easily reversible lymphopenia [275]. Despite similar therapeutic effects, an almost complete
absence of adverse events was observed [275]. Similarly, but more recently, BMS-986104 was shown to
act equivalently efficient to fingolimod in a T cell transfer colitis model, although not conveying as
many cardiovascular and pulmonary adverse events in in vitro settings [276]. Moreover, cenerimod
(ACT-334441) could also be confirmed as a potent and selective S1P1 agonistic signaling properties,
whilst broncho- and vasoconstrictive effects were not clinically relevant [277]. In humans, cenerimod
showed an improvement in disease activity scores for systemic lupus without constraining an
acceptable safety profile [278]. In contrast to these specific and well-tolerable agents, GSK2018682,
another S1P1 agonist, did bring about bradycardia and subsequent AV-block [279]. In contrast,
BMS-986104 and cenerimod seem to have a favorable risk profile in comparison to fingolimod, which,
of course, warrants further investigation in in vivo studies to determine its safety and efficacy in other
conditions. Interestingly, in pancreatic islet transplantation, which at least in humans is a definitive
treatment for type 1 diabetes mellitus denoted by high mortality and morbidity in the early phase
after transplantation [280], KRP203 was shown to cause a marked increase in viable pancreatic islet
transplants in C57BL/10 mice [281]. Nevertheless, KRP203 is not an entirely selective S1P1 agonist, as it
does bind to S1P3 with 5-fold and to S1P2 and S1P5 100-fold lesser selectivity [281]. Thus, concerns
regarding adverse effects, particularly with potentially increased doses necessary and depending
on pharmacogenetics, should govern careful investigations in humans. Lastly with respect to S1P1
specific compounds, ponesimod (ACT-128800) was previously reported to display therapeutic efficacy
in psoriasis whilst also distinguishing itself by swift reversibility upon discontinuation; however,
some degree of cardiac effects was detected in clinical trials [282].
It may be advised, under some conditions, to exploit multiple S1PR pathways. S1P5, for example,
is implicated in having pro-fibrotic effects to act on proliferation and its involvement in early
transforming-growth-factor-β (TGF-β)-signaling [283]. Therefore, fibrotic conditions or tissue scarring
might be well-suited for treatment with an agent synthesized to evoke agonistic effects both against
S1P1 and S1P5. Three compounds are currently being tested, which act in this pharmacological manner,
namely: ceralifimod (ONO-4641), ozanimod (RPC1063), and siponimod (BAF312).
Ceralifimod (ONO-4641), 1-((6-(2-methoxy-4-propylbenzyl)oxy)-1-methyl-3,4-dihydronaphthalen
-2-yl)methyl)azetidine-3-carboxylic acid 13n was recently synthesized in 2017 [284]. Beside ceralifimod,
ozanimod (RPC1063), which acts similarly, was shown to cause beneficial effects in patients with
multiple sclerosis and ulcerative colitis alike [285]. In addition, the authors found that ozanimod
wielded strong influence on the innate immune cells. Here, plasmacytoid dendritic cells were lowered
(potentially by means of sequestration), which, in turn, reduced interferon alpha (IFN-α) in lupus
patients in addition to reducing the entirety of B cell and T cell subsets in the spleen [285].
Lastly, agents that not only depicted S1P1 and S1P5 agonistic features but that also were partially
able to engage with S1P4 were identified. This cohort of compounds currently comprises amiselimod
(MT-1303) and etrasimod (APD334). The potential of being able to engage with S1P4 may hold promising
therapeutic benefits. In this regard, S1P4, as discussed previously in this review, is predominantly
expressed in lymphoid tissues [88,95], and ligation and its subsequent signaling are involved in
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marking time regarding proliferation [286,287], a reduction of effector cytokines secreted [286,287],
and migration of lymphocytes [288,289]. It is worth noting that amiselimod displays a very safe risk
profile [290–292], while it is too early to consistently assess this for etrasimod [293]. Their application
and/or investigation regarding their future therapeutic exploitability in neurological conditions should
find due consideration soon.
4. Conclusions
In this review, we described the complexities of the sphingosine 1-phosphate (S1P) signaling
in neurological conditions in reflection of currently available S1P signaling targeted drugs. Starting
with the de novo synthesis of S1P either at the smooth endoplasmic reticulum or other subcellular
microdomains, we highlighted the currently established signaling pathways. However, S1P signaling
also occurs after secretion and transportation by its chaperones HDL or albumin in the extracellular
compartment, allowing either autocrine or paracrine signaling upon ligation to S1P1–5. It was
highlighted that each S1PR subtype is capable of coupling to a variety of heterotrimeric G proteins,
subsequently allowing a tailored intracellular signaling cascade to be incited. However, under perturbed
circumstances, the presence of co-activators, inhibitors of S1PR, or simply skewed S1PR patterns may
predispose for disease onset and progression. Despite remarkable advances in understanding the
contribution of sphingolipid signaling to neurological disorders, the field has yet a lot to learn. In this
review, we highlighted the currently available literature regarding perturbations of the sphingolipid
metabolism in the context of neurodegenerative, neuroinflammatory, and cerebrovascular diseases.
A considerable number of clinical trials are being carried out testing S1P signaling targeted drugs in
conditions linked to activation of the immune system. These trials may enhance our understanding
of the importance of the S1P–S1PR axis and ultimately help to inform us about future therapeutic
usability of these compounds in various neurological disorders. We reported on the importance of
S1P1 for vascular and other barrier functions. Activation of S1P1 causes a significant improvement of
vascular barrier properties and prevents microvascular leakage. Currently available drugs interacting
with S1P1 initially act as agonists but then may cause a profound and long-lasting desensitization
and degradation of S1P1. As outlined above, they finally act as functional antagonists with, in the
long term, negative impact on vascular integrity. Currently, there is no pure S1P1 receptor agonist
available that does not desensitize the receptor. The compounds described thus far may indeed have a
varying degree of agonistic and antagonistic properties. However, such a “true agonist” would be
highly desirable and unique in order to protect from vascular leakage.
Author Contributions: A.L. and J.S. contributed equally to the design and the conception of this article and
wrote the entire manuscript. R.B., J.M.P., and W.P. critically edited the manuscript and supervised the writing.
All authors have read and agreed to the published version of the manuscript.
Funding: The authors would like to acknowledge the support by the Open Access Publication Fund of the Goethe
University Frankfurt. R.B., J.M.P., and W.P. are funded by the German Research Organization (DFG; SFB1039).
J.M.P. and W.P. are funded by the Fondation Leducq (SphingoNet). J.M.P. is funded by the Uniscientia Foundation
Vaduz. J.S. is funded by a scholarship from the German Academic Scholarship Foundation (Studienstiftung des
deutschen Volkes).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
AD Alzheimer’s disease
Akt RAC-alpha serine/threonine-protein kinase
ALS Amyotrophic lateral sclerosis
aPC Activated protein C
ApoM Apolipoprotein M
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APP Amyloid precursor protein
Aβ Amyloid-β-peptide
BBB Blood brain barrier
CBAs Conjugated bile acids
CBF Cerebral blood flow
CCL4 C-C motif chemokine 4-like
CCL5 C-C motif chemokine 5-like
CCO Cytochrome c oxidase
CCR7 C-C chemokine receptor type 7
CD Cluster of differentiation molecule
CDase Ceramidase
c-fos Proto-oncogene c-Fos
cIAP2 Cellular inhibitor of apoptosis 2
CNS Central nervous system
COX-2 Cyclooxygenase-2
CXCL8 C-X-C motif chemokine 8, IL-8
CXCL10 C-X-C motif chemokine 10
DHHC5 Palmitoyltransferase DHHC5
DNA Desoxyribonucleic acid







GRK2 G protein-coupled receptor kinase 2
Gαi/o Inhibitory Gα subunit
Gαq q subtype of Gα proteins
Gαs Stimulatory Gα subunit
G12/13 12/13 subtype of Gα proteins
HD Huntigton’s disease
HDAC1/2 Histone deacetylases 1/2
HDL High-density lipoprotein
hTERT Human telomerase reverse transcriptase
IC Intracellular





IRF1 Interferon regulatory factor 1
IκB Inhibitor of nuclear factor κ-B kinase
IκBα NF-κB inhibitor α
LBD Lewy body disorders
LDL Low-density lipoprotein
LPP Lipid phosphate phosphohydrolase
MCAO Middle cerebral artery occlusion
MFSD2B Major facilitator superfamily domain-containing protein 2B
MKRN1 Makorin ring finger protein 1
MMP-9 Matrix metalloproteinase-9
mRNA Messenger ribonucleic acid
MS Multiple slerosis
NF-κB Nuclear factor κ-light-chain-enhancer of activated B cells
NMO Neuromyelitis optica
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NVU Neurovascular unit





PGC1β PPARγ co-activator 1β
PHB2 Prohibitin-2
PKC Protein kinase C
PKCζ Atypical PKC subtype ζ
PKCι Atypical PKC subtype ι
PLPP3 Phospholipid phosphatase 3
PM Plasma membrane
PPARγ Peroxisome proliferator activated receptor γ
PTX3 Pentraxin-related protein 3
p21 Cyclin-dependent kinase inhibitor 1
RACK Receptor for activated C kinase proteins
RhoA Transforming protein RhoA
RING Really interesting new group
RIP1 Receptor-interacting serine/threonine-protein kinase 1
rt-PA Recombinant-tissue plasminogen activator
SAH Subarachnoid hemorrhage
sER Smooth endoplasmic reticulum
SGPL1 S1P lyase 1
SGPP1/2 Sphingosine 1-phosphate phosphohydrolase 1/2
SLE Systemic lupus erythematosus
SMase Sphingomyelinase
SMS Sphingomyelin synthase
SphK1 Sphingosine kinase 1
SphK2 Sphingosine kinase 2
SPNS2 Spinster homolog 2
SPT Serine palmitoyltransferase
STAT3 Signal transducer and activator of transcription 3
S1P Sphingosine 1-phosphate
S1PR Sphingosine 1-phosphate receptor
S1P1–5 S1PR subtype 1–5
TAB3 TGF-β-activated kinase 1 and MAP3K7-binding protein3
TFH Follicular TH cell
TGF-β Transforming-growth-factor-β
TH-17 TH-17 type cell
TNFRSF12A Tumor necrosis factor receptor superfamily member 12A
TNF-α Tumor necrosis factor-α
TRAF2 TNF-α receptor-associated factor 2
TRAF6 TNF-α receptor-associated factor 6
TREG Regulatory T cell
TUNEL
Terminal deoxynucleotidyl transferase-mediated, uridine 5′triphosphate-biotin nick
end-labeling
UGT8A UDP galactosyltransferase 8A
VEGFa Vascular endothelial growth factor A
VLDL Very low-density lipoprotein
WWP2 NEDD4-like E3 ubiquitin ligase WWP2
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